A Pilot Randomized, Controlled, Double‐Blind Trial of Bumetanide to Treat Neonatal Seizures

Abstract

Objective In the absence of controlled trials, treatment of neonatal seizures has changed minimally despite poor drug efficacy. We tested bumetanide added to phenobarbital to treat neonatal seizures in the first trial to include a standard‐therapy control group. Methods A randomized, double‐blind, dose‐escalation design was employed. Neonates with postmenstrual age 33 to 44 weeks at risk of or with seizures were eligible. Subjects with electroencephalography (EEG)‐confirmed seizures after ≥20 and <40mg/kg phenobarbital were randomized to receive additional phenobarbital with either placebo (control) or 0.1, 0.2, or 0.3mg/kg bumetanide (treatment). Continuous EEG monitoring data from ≥2 hours before to ≥48 hours after study drug administration (SDA) were analyzed for seizures. Results Subjects were randomized to treatment (n = 27) and control (n = 16) groups. Pharmacokinetics were highly variable among subjects and altered by hypothermia. The only statistically significant adverse event was diuresis in treated subjects (48% vs 13%, p = 0.02). One treated (4%) and 3 control subjects died (19%, p = 0.14). Among survivors, 2 of 26 treated subjects (8%) and 0 of 13 control subjects had hearing impairment, as did 1 nonrandomized subject. Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3.1 vs 1.2 min/h, p = 0.006). There was significantly greater reduction in seizure burden 0 to 4 hours and 2 to 4 hours post‐SDA (both p < 0.01) compared with 2‐hour baseline in treatment versus control groups with adjustment for seizure burden. Interpretation Although definitive proof of efficacy awaits an appropriately powered phase 3 trial, this randomized, controlled, multicenter trial demonstrated an additional reduction in seizure burden attributable to bumetanide over phenobarbital without increased serious adverse effects. Future trials of bumetanide and other drugs should include a control group and balance seizure severity. ANN NEUROL 2021;89:327–340

A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia

“…However, in a first proof‐of‐concept clinical trial on intravenous bumetanide as an add‐on to phenobarbital for treatment of neonatal seizures, bumetanide did not improve seizure control but increased the risk of hearing loss 9 . A more recent clinical trial reported a modest increase of phenobarbital's effect on neonatal seizure burden by bumetanide, 10 but, again, bumetanide was associated with increased risk of ototoxicity.…”

The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results

“…By its action on NKCC1, it blocks chloride influx and thus modulates the excitatory action of γ-aminobutyric acid (GABA) in the immature brain. 68,69 Radiprodil, a selective inhibitor of the NR2B subunit of the N-methyl-D-aspartate receptor, is also under…”

Don’t Get BUM’d Out: Bumetanide May yet Prove Beneficial for Neonatal Seizures

“…6 The first multicenter, randomized, double-blind clinical trial of BUM for the treatment of neonatal seizures was published recently. 7 The results of this pilot study have been long awaited for several reasons.…”